|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Warner-Lambert
gptkb:Hospira
Wyeth
Acquired Wyeth in 2009
|
|
gptkbp:awards
|
gptkb:Fortune_500
gptkb:sustainable_development
Best Places to Work
World's Most Admired Companies
Top Employers
|
|
gptkbp:capital
|
over $200 billion
approximately 200 billion USD (2021)
|
|
gptkbp:ceo
|
gptkb:Albert_Bourla
|
|
gptkbp:clinical_trial
|
gptkb:vaccine
rare diseases
antibiotics
autoimmune diseases
respiratory diseases
oncology drugs
Phase 3 trials for COVID-19 vaccine
cardiovascular drugs
COVID-19 treatments
pain management drugs
neurology drugs
conducts clinical trials globally
HIV drugs
diabetes drugs
hepatitis drugs
mental health drugs
|
|
gptkbp:collaborated_with
|
government agencies for vaccine distribution
|
|
gptkbp:collaboration
|
gptkb:GAVI_Alliance
gptkb:Global_Fund
gptkb:CEPI
gptkb:World_Health_Organization
|
|
gptkbp:conducts_research_on
|
gptkb:Mikael_Dolsten
|
|
gptkbp:developed_by
|
gptkb:Paxlovid
gptkb:vaccine
|
|
gptkbp:employees
|
approximately 78,500
approximately 78,500 (2020)
over 78,000
Over 78,000
|
|
gptkbp:employs
|
over 78,000 people
|
|
gptkbp:focus
|
Pharmaceuticals
|
|
gptkbp:founded
|
1849
|
|
gptkbp:founded_in
|
1849
|
|
gptkbp:founder
|
gptkb:Charles_Pfizer_Jr.
|
|
gptkbp:funding
|
the U. S. government for vaccine development
|
|
gptkbp:global_presence
|
over 125 countries
operates in over 125 countries
|
|
gptkbp:has_a_focus_on
|
rare diseases
innovation in healthcare
digital health solutions
improving healthcare access.
|
|
gptkbp:has_a_presence_in
|
the biotechnology sector
|
|
gptkbp:has_a_research_and_development_budget_of
|
over $10 billion annually
|
|
gptkbp:has_developed_treatments_for
|
cardiovascular diseases
|
|
gptkbp:has_diversity_initiatives
|
therapeutics and vaccines
|
|
gptkbp:has_faced_lawsuits_regarding
|
vaccine side effects
|
|
gptkbp:has_history
|
mergers and acquisitions
philanthropic efforts
|
|
gptkbp:has_partnerships_with
|
various healthcare organizations
|
|
gptkbp:has_role
|
vaccine supply chain management
COVID-19 public health response
COVID-19 variant research
|
|
gptkbp:headquarters
|
gptkb:New_York_City,_New_York
gptkb:Manhattan
gptkb:New_York_City
gptkb:New_York_City,_USA
gptkb:Manhattan,_New_York
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pfizer
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:is_a_member_of
|
the Pharmaceutical Research and Manufacturers of America (Ph RMA)
|
|
gptkbp:is_committed_to
|
diversity and inclusion in the workplace
sustainability and corporate responsibility
patient access to medicines
transparency in clinical trials
|
|
gptkbp:is_displayed_in
|
gptkb:New_York_Stock_Exchange
|
|
gptkbp:is_involved_in
|
clinical research
global health initiatives
global vaccination efforts
healthcare policy advocacy
biopharmaceutical research
|
|
gptkbp:is_known_for
|
collaborative research efforts
patient-centered approach
research in oncology
collaborative vaccine development efforts
developing vaccines and medicines
|
|
gptkbp:is_recognized_for
|
scientific research contributions
its contributions to public health
leadership in vaccine technology
safety protocols in drug development
|
|
gptkbp:is_vulnerable_to
|
gptkb:BNT162b2
gptkb:vaccine
gptkb:Comirnaty
global
fatigue
headache
muscle pain
academic institutions
generally positive
fever
joint pain
December 11, 2020
two doses
chills
billions of dollars
injection site pain
reduced hospitalization rates
contributed to herd immunity
95% in preventing COVID-19
reduced severe cases
important for uptake
ongoing surveillance
|
|
gptkbp:leadership
|
vaccine development
|
|
gptkbp:notable_player
|
the global vaccine market
|
|
gptkbp:participated_in
|
clinical trial registries
|
|
gptkbp:partnership
|
gptkb:Eli_Lilly
gptkb:Sagent_Pharmaceuticals
gptkb:GSK
gptkb:pharmaceuticals
gptkb:Johnson_&_Johnson
gptkb:Aurobindo_Pharma
gptkb:Takeda_Pharmaceutical_Company
gptkb:Mylan
gptkb:Partnership_with_Bio_NTech_for_COVID-19_vaccine
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Alvogen
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Baxter_International
gptkb:Regeneron_Pharmaceuticals
gptkb:Moderna
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Amgen
gptkb:Gilead_Sciences
gptkb:Sandoz
gptkb:Hikma_Pharmaceuticals
gptkb:Astellas_Pharma
gptkb:Eli_Lilly_and_Company
gptkb:Vertex_Pharmaceuticals
gptkb:Lupin_Pharmaceuticals
gptkb:Sun_Pharmaceutical_Industries
gptkb:Abb_Vie
gptkb:Celgene
gptkb:Novartis
gptkb:Bio_NTech
gptkb:Zydus_Cadila
gptkb:Dr._Reddy's_Laboratories
Perrigo Company
|
|
gptkbp:philanthropy
|
gptkb:Pfizer_Foundation
global health initiatives
COVID-19 relief efforts
|
|
gptkbp:produced
|
gptkb:Comirnaty
|
|
gptkbp:products
|
antibiotics
vaccines
oncology drugs
cardiovascular drugs
|
|
gptkbp:provided
|
COVID-19 treatment options
|
|
gptkbp:received_emergency_use_authorization_for
|
gptkb:vaccine
|
|
gptkbp:received_emergency_use_authorization_from
|
gptkb:FDA
|
|
gptkbp:reported_efficacy_of
|
95% for COVID-19 vaccine
|
|
gptkbp:research
|
gptkb:cancer_treatment
rare diseases
antibiotics
inflammation
neuroscience
vaccine development
|
|
gptkbp:research_and_development
|
gptkb:gene_therapy
vaccines
biopharmaceuticals
m RNA technology
|
|
gptkbp:revenue
|
over $50 billion
41.9 billion USD (2020)
|
|
gptkbp:service_area
|
Worldwide
|
|
gptkbp:stock_symbol
|
PFE
|
|
gptkbp:subsidiaries
|
gptkb:Pfizer_Consumer_Healthcare
gptkb:Pfizer_Animal_Health
gptkb:Upjohn
|
|
gptkbp:subsidiary
|
gptkb:Pfizer_Consumer_Healthcare
gptkb:Pfizer_Animal_Health
gptkb:Upjohn
|
|
gptkbp:sustainability_efforts
|
community engagement
diversity and inclusion
ethical business practices
environmental responsibility
|
|
gptkbp:sustainability_initiatives
|
community engagement
environmental responsibility
access to medicines
|
|
gptkbp:traded_on
|
gptkb:NYSE
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:vaccine_age_approval
|
12 years and older
|
|
gptkbp:vaccine_booster_recommendation
|
6 months after second dose
|
|
gptkbp:vaccine_booster_studies
|
ongoing research
|
|
gptkbp:vaccine_clinical_trial_demographics
|
diverse populations
|
|
gptkbp:vaccine_clinical_trial_participants
|
over 43,000
|
|
gptkbp:vaccine_clinical_trial_phases
|
Phase 1, Phase 2, Phase 3
|
|
gptkbp:vaccine_clinical_trial_results_publication
|
peer-reviewed journals
|
|
gptkbp:vaccine_cold_chain_logistics
|
critical for distribution
|
|
gptkbp:vaccine_collaboration_with_who
|
yes
|
|
gptkbp:vaccine_communication_strategy
|
public health campaigns
|
|
gptkbp:vaccine_distribution_partners
|
various governments
|
|
gptkbp:vaccine_effectiveness_against_variants
|
decreased
|
|
gptkbp:vaccine_effectiveness_studies
|
conducted post-authorization
|
|
gptkbp:vaccine_global_distribution_efforts
|
collaborative initiatives
|
|
gptkbp:vaccine_global_health_impact
|
gptkb:significant
|
|
gptkbp:vaccine_impact_on_transmission
|
reduced transmission rates
|
|
gptkbp:vaccine_long-term_studies
|
ongoing
|
|
gptkbp:vaccine_misinformation
|
a significant issue
|
|
gptkbp:vaccine_misinformation_countermeasures
|
education campaigns
|
|
gptkbp:vaccine_monitoring_system
|
VAERS
|
|
gptkbp:vaccine_name_origin
|
combination of community and immunity
|
|
gptkbp:vaccine_patent_status
|
patented
|
|
gptkbp:vaccine_production_capacity
|
billions of doses
|
|
gptkbp:vaccine_public_health_role
|
key in pandemic response
|
|
gptkbp:vaccine_regulatory_approvals
|
multiple countries
|
|
gptkbp:vaccine_research_transparency
|
important for trust
|
|
gptkbp:vaccine_role_in_reopening_economies
|
critical
|
|
gptkbp:vaccine_rollout_strategy
|
phased approach
|
|
gptkbp:vaccine_storage_duration
|
up to 30 days in refrigerator
|
|
gptkbp:vaccine_storage_requirement
|
-70 degrees Celsius
|
|
gptkbp:vaccine_supply_agreements
|
various nations
|
|
gptkbp:vaccine_supply_chain_challenges
|
logistical issues
|
|
gptkbp:vaccine_technology
|
lipid nanoparticles
|
|
gptkbp:was_involved_in
|
vaccine education campaigns
|
|
gptkbp:website
|
pfizer.com
www.pfizer.com
|
|
gptkbp:bfsParent
|
gptkb:biotechnology
gptkb:W3_C
gptkb:General_Electric
|
|
gptkbp:bfsLayer
|
3
|